drugset

drugset / Trial / NCT06125652

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

NCT06125652 ↗

Phase 1/2 Recruiting 20 enrolled Xuzhou Medical University

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

Timeline

Start: 2023-11-04
Primary completion: 2026-01-01
Completion: 2027-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sym023	Monoclonal antibody	—	—

Indications